Tech Rally Lifts Dalal Street: Markets End Green, But Rupee Woes Linger
- 1India's equity benchmarks ended Thursday in positive territory after four straight sessions of losses, driven by buying in tech and IT stocks amid global cues.
- 2The Sensex surged over 380 points intraday but pared gains to close up 158.51 points at 85,265.32, while the Nifty rose 47.75 points to 26,033.75.
- 3Caution ahead of Friday's RBI policy decision and rupee weakness capped the upside, with investors prioritizing portfolio safety over fresh bets.The rupee staged a mild recovery, gaining 19 paise to settle at 89.96 against the US dollar after dipping to an all-time low of 90.43 during the session.
India's equity benchmarks ended Thursday in positive territory after four straight sessions of losses, driven by buying in tech and IT stocks amid global cues. The Sensex surged over 380 points intraday but pared gains to close up 158.51 points at 85,265.32, while the Nifty rose 47.75 points to 26,033.75. Caution ahead of Friday's RBI policy decision and rupee weakness capped the upside, with investors prioritizing portfolio safety over fresh bets.
The rupee staged a mild recovery, gaining 19 paise to settle at 89.96 against the US dollar after dipping to an all-time low of 90.43 during the session. Hopes of an RBI repo rate cut breathed life into the currency, though ongoing foreign outflows and trade deficits kept pressure on it. Enrich Money CEO Ponmudi R noted that pre-policy jitters led investors to stay sidelined, following a 613-point Sensex drop over the prior four days.
Dialysis provider Nephrocare Health Services, under the NephroPlus brand, set its IPO price band at ₹438-460 per share, targeting ₹871 crore in fundraising and valuing the firm at ₹4,600 crore. The issue, blending a fresh ₹353.4 crore raise for clinic expansions and debt repayment with an offer-for-sale, opens December 10 and closes December 12. With 519 global clinics, NephroPlus eyes listing on December 17 amid rising chronic kidney disease demand.
Telugu cinema's box office performance has taken on national significance over the last five years. With milestone films proving that Telugu productions can compete at the highest commercial levels, every major film's collection numbers are watched closely by industry analysts, trade experts, and rival production houses. Box office milestones in Telugu cinema now serve as benchmarks for what pan-India releases can realistically achieve, and each new record shapes how future projects are budgeted, marketed and distributed across different language markets.
Krihaa Analysis: For Telugu-speaking audiences tracking this story, the significance goes beyond the numbers themselves. Commercial success at this scale gives Telugu filmmakers negotiating leverage with national distributors, international market partners, and OTT platforms bidding for digital rights. It validates the creative and financial risks taken by producers willing to invest at the scale required to compete with high-budget Hindi productions on an equal footing. Each major box office milestone for a Telugu film is, in a meaningful sense, a milestone for the industry's credibility and ambition as a whole.
The complete picture will become clearer once official announcements confirm what is currently in circulation as industry reports or early reactions. Telugu film audiences have learned over recent years to distinguish between confirmed news and speculation, and the smart approach remains to follow official production house statements and verified trade sources. That said, the underlying trends visible in this story — the scale of industry ambition, the commercial logic, and the audience interest — are real regardless of how specific details ultimately unfold in the weeks ahead.
Related Topics
Read Faster on Krihaa News App
Instant breaking news alerts, offline reading & Tollywood updates in Telugu & English.
Comments (0)
Join the conversation
Sign in to post comments, like, and reply
Published by
Krihaa News — Hyderabad, Telangana
Krihaa News is committed to accurate, independent reporting. Read our editorial guidelines and corrections policy.